Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms-Reference-Cited by-同舟云学术

Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms

Published:2005-07-05 Issue:3 Volume:8 Page:253-259
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Quinn J E,Brown L G,Zhang J,Keller E T,Vessella R L,Corey E

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

http://www.nature.com/articles/4500815.pdf

Reference26 articles.

1. Clarke NW, McClure J, George NJR . Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol 1991; 68: 74–80.

2. Nemeth JA et al. Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002; 94: 17–25.

3. Zhang J et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001; 107: 1235–1244.

4. Corey E et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003; 9: 295–306.

5. Lee MV et al. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61: 2602–2608.

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The association between RANKL and Osteoprotegerin gene polymorphisms with breast cancer;Molecular and Cellular Biochemistry;2015-02-28

2. RANK rs1805034 T>C Polymorphism Is Associated with Susceptibility of Esophageal Cancer in a Chinese Population;PLoS ONE;2014-07-14

3. Bone Markers for Monitoring Efficacy in Patients with Bone Metastases Receiving Zoledronic Acid: A Review of Published Data;The International Journal of Biological Markers;2013-07

4. The role of the bone microenvironment in skeletal metastasis;Journal of Bone Oncology;2013-02

5. Expression of osteoprotegerin from a replicating adenovirus inhibits the progression of prostate cancer bone metastases in a murine model;Laboratory Investigation;2013-01-28